News und Analysen

On Tuesday, Massachusetts-based Lane Generational disclosed that it sold out of Bruker (NASDAQ:BRKR), liquidating 87,607 shares for an estimated $3.6 million in the third quarter.

According to a

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck

Novo Nordisk's (NYSE: NVO) shares have dropped significantly over the past year, partly due to clinical setbacks in its core GLP-1 portfolio. However, the Denmark-based pharmaceutical leader has

Harbor Capital Advisors disclosed the sale of over 300,000 shares of RadNet (NASDAQ:RDNT) in Q3 2025. The trade was worth an estimated $19.74 million.

According to a filing with the Securities and

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook. Scooping up shares of great companies after they have experienced

When a country changes which assets it holds in reserve on its central bank's balance sheet, markets notice, and with good reason. Similarly, when a major economy even flirts with the idea of

Pfizer (NYSE: PFE) is one of the oldest and most respected pharmaceutical companies in the world. The stock is out of favor right now, trading down around 60% from its 2022 high-water mark. The

Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in the world by market cap, largely thanks to its work in diabetes drugs and, more

I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks

Schwartz Investment Counsel disclosed that it reduced its position in Chemed Corporation (NYSE:CHE) by 28,771 shares during the quarter, according to a 13F form filed with the Securities and

Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held

Viking Therapeutics (NASDAQ: VKTX) leaped onto center stage early last year when it announced promising news about a candidate addressing an area of soaring demand: weight loss. The biotech then

Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and

AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the

It can take a while for growth stocks to reach their full potential, which is why they can make for good long-term options to hang on to. Along the way, however, they can encounter difficulties that

Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by

Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares

Fenimore Asset Management Inc. fully exited its position in Waters Corporation (NYSE:WAT), selling approximately $85.09 million in shares.

According to a Q3 2025 filing submitted to the U.S

On October 28, 2025, EULAV Asset Management reported selling 28,313 shares of Chemed (NYSE:CHE) in Q3 2025, an estimated $12.82 million trade based on the average price during Q3 2025.

According to

Shares of DexCom (NASDAQ: DXCM), a medical device specialist, have lagged the broader market so far in 2025, down 11% year to date. The diabetes-focused healthcare company has faced several legal

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list

The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.

What does